Abel, Melissa LKokosis, GeorgeBlazer, Dan G2017-08-282017-08-282017-02-20https://hdl.handle.net/10161/15384© 2016 The Author(s). Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades. Case presentation: Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C. Conclusions: While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.Pulmonary toxicity after intraperitoneal mitomycin C: A case report of a rare complication of HIPECJournal article1477-7819